{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:50:15Z","timestamp":1782492615854,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2010432"],"award-info":[{"award-number":["W81XWH2010432"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-HL098054"],"award-info":[{"award-number":["T32-HL098054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL155159"],"award-info":[{"award-number":["R01-HL155159"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-HL168419"],"award-info":[{"award-number":["U01-HL168419"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ccc.2023.12.002","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T07:28:12Z","timestamp":1703834892000},"page":"275-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacologic Treatments in Acute Respiratory Failure"],"prefix":"10.1016","volume":"40","author":[{"given":"Elizabeth","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10300","key":"10.1016\/j.ccc.2023.12.002_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","article-title":"Acute respiratory distress syndrome","volume":"398","author":"Meyer","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-0039-1683996","article-title":"Pathogenesis of acute respiratory distress syndrome","volume":"40","author":"Huppert","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(17)30188-1","article-title":"Clinical trials in acute respiratory distress syndrome: challenges and opportunities","volume":"5","author":"Matthay","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ccc.2023.12.002_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201703-0548ST","article-title":"An official american thoracic society\/european society of intensive care medicine\/society of critical care medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome","volume":"195","author":"Fan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib5","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1007\/s00134-020-06289-8","article-title":"Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS","volume":"46","author":"Meduri","year":"2020","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2016.0291","article-title":"Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries","volume":"315","author":"Bellani","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ccc.2023.12.002_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.chest.2021.05.047","article-title":"Variation in early management practices in moderate-to-severe ARDS in the United States: the severe ARDS: generating evidence study","volume":"160","author":"Qadir","year":"2021","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.ccc.2023.12.002_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM198712173172504","article-title":"High-dose corticosteroids in patients with the adult respiratory distress syndrome","volume":"317","author":"Bernard","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1378\/chest.92.6.1032","article-title":"Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome","volume":"92","author":"Bone","year":"1987","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1164\/ajrccm\/138.1.62","article-title":"Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock","volume":"138","author":"Luce","year":"1988","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.ccc.2023.12.002_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archsurg.1985.01390290018003","article-title":"Early steroid therapy for respiratory failure","volume":"120","author":"Weigelt","year":"1985","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.ccc.2023.12.002_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.280.2.159","article-title":"Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial","volume":"280","author":"Meduri","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ccc.2023.12.002_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1378\/chest.06-2100","article-title":"Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial","volume":"131","author":"Meduri","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccc.2023.12.002_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ccc.2023.12.002_bib15","first-page":"CD004477","article-title":"Pharmacological agents for adults with acute respiratory distress syndrome","volume":"7","author":"Lewis","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ccc.2023.12.002_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","article-title":"Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis","volume":"47","author":"Chaudhuri","year":"2021","journal-title":"Intensive Care Med"},{"issue":"16","key":"10.1016\/j.ccc.2023.12.002_bib17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa051693","article-title":"Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome","volume":"354","author":"Steinberg","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ccc.2023.12.002_bib18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","article-title":"Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia","volume":"48","author":"Meduri","year":"2022","journal-title":"Intensive Care Med"},{"issue":"21","key":"10.1016\/j.ccc.2023.12.002_bib20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMe2302544","article-title":"Time to treat severe community-acquired pneumonia with steroids?","volume":"388","author":"Metlay","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-023-04561-z","article-title":"Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Wu","year":"2023","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.ccc.2023.12.002_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.chest.2022.08.2229","article-title":"Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials","volume":"163","author":"Saleem","year":"2023","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00134-017-4919-5","article-title":"Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017","volume":"43","author":"Annane","year":"2017","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.CCM.0000104114.72614.BC","article-title":"Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome","volume":"32","author":"Gainnier","year":"2004","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccc.2023.12.002_bib25","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1097\/01.CCM.0000239435.87433.0D","article-title":"Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome","volume":"34","author":"Forel","year":"2006","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2023.12.002_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00134-016-4653-4","article-title":"Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome","volume":"43","author":"Guervilly","year":"2017","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMe1007136","article-title":"Neuromuscular blocking agents in ARDS","volume":"363","author":"Slutsky","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1005372","article-title":"Neuromuscular blockers in early acute respiratory distress syndrome","volume":"363","author":"Papazian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib29","first-page":"787","article-title":"Early neuromuscular blockade in the acute respiratory distress syndrome. reply","volume":"381","author":"Moss","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"161","key":"10.1016\/j.ccc.2023.12.002_bib30","doi-asserted-by":"crossref","first-page":"210059","DOI":"10.1183\/16000617.0059-2021","article-title":"Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome","volume":"30","author":"Gierhardt","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"25","key":"10.1016\/j.ccc.2023.12.002_bib31","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMra051884","article-title":"Inhaled nitric oxide therapy in adults","volume":"353","author":"Griffiths","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib32","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1378\/chest.14-3161","article-title":"The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis","volume":"147","author":"Fuller","year":"2015","journal-title":"Chest"},{"issue":"5 Pt 1","key":"10.1016\/j.ccc.2023.12.002_bib33","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1164\/ajrccm.157.5.96-10089","article-title":"Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS","volume":"157","author":"Michael","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"10.1016\/j.ccc.2023.12.002_bib34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1164\/ajrccm.157.5.9707090","article-title":"Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study","volume":"157","author":"Troncy","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccc.2023.12.002_bib35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s001340050982","article-title":"Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide","volume":"25","author":"Lundin","year":"1999","journal-title":"Intensive Care Med"},{"issue":"13","key":"10.1016\/j.ccc.2023.12.002_bib36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/jama.291.13.1603","article-title":"Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial","volume":"291","author":"Taylor","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ccc.2023.12.002_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/CCM.0b013e3182a27909","article-title":"Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis","volume":"42","author":"Adhikari","year":"2014","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-023-02346-0","article-title":"Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial","volume":"24","author":"Haeberle","year":"2023","journal-title":"Respir Res"},{"issue":"Suppl 1","key":"10.1016\/j.ccc.2023.12.002_bib39","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1513\/AnnalsATS.201406-254MG","article-title":"Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome","volume":"12","author":"Matthay","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s13287-019-1518-0","article-title":"Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome","volume":"10","author":"Han","year":"2019","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.ccc.2023.12.002_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccc.2023.12.002_bib42","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.eclinm.2021.101167","article-title":"Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: a phase 1 trial","volume":"41","author":"Gorman","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00134-021-06570-4","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial","volume":"48","author":"Bellingan","year":"2022","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcyt.2022.03.006","article-title":"Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019","volume":"24","author":"Whittaker Brown","year":"2022","journal-title":"Cytotherapy"},{"issue":"19","key":"10.1016\/j.ccc.2023.12.002_bib45","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ccc.2023.12.002_bib47","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2023.12.002_bib48","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 6\/1\/2023; Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"10.1016\/j.ccc.2023.12.002_bib49","unstructured":"Organization, W.H. Corticosteroids for COVID-19. 2020 6\/1\/2023; Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Corticosteroids-2020.1."},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","article-title":"Interleukin-6: obstacles to targeting a complex cytokine in critical illness","volume":"9","author":"McElvaney","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.ccc.2023.12.002_bib51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial","volume":"47","author":"Rosas","year":"2021","journal-title":"Intensive Care Med"},{"issue":"16","key":"10.1016\/j.ccc.2023.12.002_bib52","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.ccc.2023.12.002_bib53","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ccc.2023.12.002_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"23","key":"10.1016\/j.ccc.2023.12.002_bib57","first-page":"2281","article-title":"Baricitinib is first approved COVID-19 immunomodulatory Treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","article-title":"Redefining critical illness","volume":"28","author":"Maslove","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0039-1684049","article-title":"Acute respiratory distress syndrome phenotypes","volume":"40","author":"Reilly","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","article-title":"Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials","volume":"2","author":"Calfee","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ccc.2023.12.002_bib61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","article-title":"Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy","volume":"195","author":"Famous","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccc.2023.12.002_bib62","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00134-018-5378-3","article-title":"Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study","volume":"44","author":"Sinha","year":"2018","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/thoraxjnl-2021-217158","article-title":"Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study","volume":"77","author":"Sinha","year":"2022","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.ccc.2023.12.002_bib64","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccc.2023.12.002_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-med-043021-014005","article-title":"Biological phenotyping in sepsis and acute respiratory distress syndrome","volume":"74","author":"Sinha","year":"2023","journal-title":"Annu Rev Med"},{"issue":"18","key":"10.1016\/j.ccc.2023.12.002_bib66","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","article-title":"Simvastatin in the acute respiratory distress syndrome","volume":"371","author":"McAuley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccc.2023.12.002_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa032193","article-title":"Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome","volume":"351","author":"Brower","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CCM.0000000000002749","article-title":"Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration","volume":"46","author":"Meyer","year":"2018","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccc.2023.12.002_bib69","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.ccc.2023.12.002_bib70","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.ccc.2023.12.002_bib71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccc.2023.12.002_bib72","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.ccc.2023.12.002_bib73","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S2213-2600(20)30366-0","article-title":"Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study","volume":"8","author":"Sinha","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(21)00157-0","article-title":"Advancing precision medicine for acute respiratory distress syndrome","volume":"10","author":"Beitler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"23","key":"10.1016\/j.ccc.2023.12.002_bib75","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","article-title":"Rosuvastatin for sepsis-associated acute respiratory distress syndrome","volume":"370","author":"Truwit","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccc.2023.12.002_bib76","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.chest.2021.11.006","article-title":"Aspirin as a treatment for ARDS: a randomized, placebo-controlled clinical trial","volume":"161","author":"Toner","year":"2022","journal-title":"Chest"},{"issue":"10223","key":"10.1016\/j.ccc.2023.12.002_bib77","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"9812","key":"10.1016\/j.ccc.2023.12.002_bib78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)61623-1","article-title":"Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (Balti-2): a multicentre, randomised controlled trial","volume":"379","author":"Gao Smith","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccc.2023.12.002_bib79","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1164\/rccm.201012-2090OC","article-title":"Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury","volume":"184","author":"Matthay","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccc.2023.12.002_bib80","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.ccc.2023.12.002_bib81","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2019.22525","article-title":"Effect of intravenous interferon beta-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial","volume":"323","author":"Ranieri","year":"2020","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ccc.2023.12.002_bib82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","article-title":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome","volume":"342","author":"Brower","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00003246-199801000-00011","article-title":"Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group","volume":"26","author":"Dellinger","year":"1998","journal-title":"Crit Care Med"},{"issue":"23","key":"10.1016\/j.ccc.2023.12.002_bib84","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone positioning in severe acute respiratory distress syndrome","volume":"368","author":"Guerin","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccc.2023.12.002_bib85","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.conctc.2023.101155","article-title":"Design and rationale of the CHILL phase II trial of hypothermia and neuromuscular blockade for acute respiratory distress syndrome","volume":"33","author":"Shanholtz","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"10.1016\/j.ccc.2023.12.002_bib86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A\u00a0practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070423000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070423000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:23:51Z","timestamp":1782491031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070423000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0749070423000921"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2023.12.002","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatments in Acute Respiratory Failure","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}